Highlights Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Market Closed - Hong Kong S.E. Other stock markets 09:08:07 09/05/2024 BST			5-day change	1st Jan Change
40.55 ^HKD	+1.38%		+6.01%	-5.15%

05-07	Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	CI
04-30	Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	05-07	CI
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	04-02	MT
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	04-02	CI
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	04-02	CI
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	03-21	MT
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	03-07	CI
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%	03-05	MT
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer	03-05	CI
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease	02-19	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	02-15	RE
Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China	02-07	CI
Innovent Biologics Posts 65% Revenue Growth in Q4 of 2023	02-06	MT
Innovent Bio's Weight Management Drug Trial Meets Primary and Secondary Endpoints	01-09	MT
Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints	01-08	CI
Innovent Biologics, Inc. and Sanegene Bio USA Inc. Enter Strategic Collaboration to Develop Sirna Drug for the Treatment of Hypertension	12-26	CI
China?S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application of Taletrectinib	12-18	CI
Innovent Biologics, Inc. Announces Publication of Mazdutide Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications	12-17	CI
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study	12-07	CI
Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma	12-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Highlights

Filters